MedPath

Artesunate/Pyronaridine Phosphate

Generic Name
Artesunate/Pyronaridine Phosphate

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Phase 2
Completed
Conditions
COVID-19
Interventions
First Posted Date
2022-12-01
Last Posted Date
2022-12-02
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
20
Registration Number
NCT05633420
Locations
🇰🇷

Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Inha University Hospital, Incheon, Korea, Republic of

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Phase 3
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2021-10-20
Last Posted Date
2023-06-18
Lead Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Target Recruit Count
1807
Registration Number
NCT05084911
Locations
🇦🇷

Instituto Medico Platense, Buenos Aires, Argentina

🇰🇷

Seoul Red Cross Hospital, Seoul, Korea, Republic of

🇨🇴

IPS Centro Cientifico Asisitencial S.A.S, Barranquilla, Colombia

and more 63 locations

Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)

Phase 3
Completed
Conditions
Malaria in Pregnancy
Interventions
First Posted Date
2021-03-04
Last Posted Date
2022-11-04
Lead Sponsor
University of Kinshasa
Target Recruit Count
250
Registration Number
NCT04783051
Locations
🇨🇩

Maternité Esengo, Kinshasa, Congo, The Democratic Republic of the

Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

Phase 1
Completed
Conditions
Malaria
Interventions
First Posted Date
2010-07-02
Last Posted Date
2023-02-03
Lead Sponsor
Medicines for Malaria Venture
Target Recruit Count
34
Registration Number
NCT01156389
Locations
🇨🇭

Covance Clinical Research Unit AG, Allschwil, Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath